Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Coronavirus Update: J&J Shows Promise Against Omicron, UK Nod For Paxlovid

Plus Comirnaty Touted For Teens

Executive Summary

The FDA authorized Comirnaty as a booster shot for 12- to 15-year-olds, as J&J's vaccine has shown effectiveness as a booster in Omicron-dominant settings. Meanwhile, Pfizer's Paxlovid won approval in the UK, and Novavax submitted the final data for its vaccine to the FDA.

You may also be interested in...



Coronavirus Update: FDA Tries To Control J&J’s Vaccine, Extended Use Of Paxlovid

The FDA has also moved to limit use of J&J’s COVID-19 vaccine amid reports of rare but dangerous blood clots, while Regeneron highlighted efforts to get approval for REGEN-COV in its Q1 earnings.

COVID-19 Products Had Strong 2021, But Omicron Casts Shadow Over 2022

Evidence that the new variant dulls drugs and vaccines’ efficacy creates uncertainty for 2022, but new products are in the wings.

US FDA Authorizes Pfizer's Paxlovid, In The Nick Of Time

The US FDA’s Christmas gift was the authorization of the first oral pill for treatment of mild-to-moderate COVID-19; Pfizer expects to have 30 million doses of Paxlovid available by mid-2022.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC145643

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel